Background: Osteoprotegerin (OPG) and fibroblast growth factor-23 (FGF23) are recognized as strong risk factors of vascular calcifications in non dialysis chronic kidney disease (ND-CKD) patients. The aim of this study was to investigate the relationships between FGF23, OPG, and coronary artery calcifications (CAC) in this population and to attempt identification of the most powerful biomarker of CAC: FGF23? OPG?
Introduction
Coronary artery calcifications (CAC) are recognized as a strong predictor of all-cause and cardiovascular mortality in hemodialysis (HD) patients [1] . Recent studies now provide strong evidence for the risk of death with a high CAC score in chronic kidney disease (CKD) patients before onset of dialysis [2, 3] . Presence of CAC has been associated with numerous traditional risk factors including aging, hypertension and diabetes as well as with non traditional risk factors including mineral metabolism disorders, hyperparathyroidism, inflammation, osteoprotegerin (OPG) and more recently fibroblast growth factor 23 (FGF23) [4] .
OPG is a bone regulating protein belonging to the TNF receptor superfamily. With its ligand, the receptor activator of nuclear factor kB ligand (RANKL), it regulates important aspects of osteoclast/osteoblast formation [5] . RANKL increases the pool of active osteoclasts by activating its specific receptor RANK located partly on osteoclastic cells, thus increasing bone resorption, whereas OPG, which neutralizes RANKL, has opposite effects. RANKL and OPG are produced by bone marrow derived stromal cells and osteoblasts and are regulated by various calcitropic cytokines, hormones, and drugs. The actions of OPG and RANKL in the vasculature and heart are still unclear but no doubt exists about the strong association of OPG with the prevalence of vascular calcifications in predialysis [6] and HD patients [7] .
FGF23 is the main regulator of phosphate homeostasis. It is produced by osteocytes in response to hyperphosphatemia and exerts its effects on its receptor, the Klotho-FGFR1c heterodimer, in the kidney where it inhibits the expression of Na-Pi cotransporters resulting in hyperphosphaturia. Literature data are more controversial regarding FGF23 association with vascular calcifications according to the stage of CKD. Relationships between FGF23 and aortic calcifications [8] or peripheral vascular calcifications [9, 10] are well documented in HD patients. By contrast, studies in non dialysis CKD (ND-CKD) patients could not evidence any association after multivariable adjustment [11] but rather relationships to atherosclerosis [12] and left ventricular hypertrophy [11, 13] .
We therefore investigated in this cross-sectional study the relationships between FGF23, OPG and CAC prevalence in a population of ND-CKD patients and attempted to identify the most powerful biomarker(s) of CAC: FGF23? OPG?
Methods

Ethics Statement
The study was conducted according to the principles of the Declaration of Helsinki and in compliance with International Conference on Harmonization/Good Clinical Practice regulations. According to the French Law, the study has been registered at ''Ministère de la Santé et des Solidarités'' after approval by the Montpellier University Hospital's ethics committee (Comité de Protection des Personnes Sud Méditerranée IV) with the following number 2006-A00416-45. All patients gave their written informed consent.
Subjects
One hundred and ninety five ND-CKD patients at various stages of kidney disease, issued from the outpatient general nephrology consultation of the Montpellier Lapeyronie university hospital, were enrolled in this cross-sectional study. Inclusion criteria were age$18 years and presence of CKD defined by glomerular filtration rate (GFR) in agreement with the National Kidney Foundation [14] .
Causes of CKD were glomerulonephritis (n = 25), cystic renal disease (n = 14), diabetic nephropathy (n = 21), diabetic and hypertensive nephropathy (n = 21), angiosclerosis and hypertensive nephropathy (n = 79), infectious/obstructive interstitial nephropathy (n = 4), renal neoplasia (n = 1), genetic/congenital cause (n = 1), necrotizing angiitis (n = 3), unknown cause (n = 9), other cause (n = 17).
Detailed medical history including age, gender, weight, height, diabetes mellitus, hypertension, past or current smoking, presence of atherosclerotic cardiovascular disease was recorded.
Existence of hypertension was defined by brachial blood pressure higher or equal to 130/80 mmHg and/or by a current antihypertensive treatment.
Presence of atherosclerotic cardiovascular disease was defined by the presence of at least one of the three following manifestations: coronary heart disease (CHD), cerebrovascular disease (CVD) or peripheral vascular disease (PVD). CHD was defined as documented angina pectoris or history of myocardial infarction. Angina pectoris was described as chest pain arising at exertion and disappearing with nitroglycerine or rest. The diagnosis may also have been made by a positive evaluation in nuclear medicine or a coronary stenosis .75% of luminal diameter evidenced by angiography. Myocardial infarction was defined as clinical symptoms, such as chest pain or dyspnea, associated with abnormal electrocardiogram and elevated troponins. CVD was defined as previous clinical cerebral disease ( [15, 16] .
GFR was estimated using the reexpressed 4-variable Modification of Diet in Renal Disease (MDRD) study equation [17] .
Urinary PO 4 Coronary artery calcification imaging. All patients underwent multidetector computed tomography (MDCT).
Regarding data acquisition, all MDCT scans derived from a multidetector-row spiral CT (Lightspeed VCT, General Electric Medical System, Milwaukee, WI, USA). Prospective ECGtriggered step-scan was performed using with 2.5-mm collimation width 664 detectors so that the center of the temporal window corresponded to 70% of the R-R interval. The scanning parameters were a gantry rotation speed of 0.35 s/rotation, 120 kV and 300 mA 862.5 collimation, and 20 mm table feed per rotation. The matrix size was 5126512 pixels and the display field of view was 25 cm. The reconstruction kernel was standard. The temporal resolution was 250 ms.
Regarding image evaluation, calcium score was calculated using a semi-automatically software (Smartscore version 3.5, Advantage Window 4.4 workstation, General Electric, Milwaukee, WI, USA). Coronary calcification was defined as a plaque of . = 4 pixels (area = 1.37 mm 2 ) with a density of greater than or equal to 130 Hounsfield units. Quantitative calcium scores were calculated according to the method described by Agatston et al. [18] . Coronary calcium scoring was performed by either a physician or computed tomography technician with specific training for the methodology described above.
Statistical Methods
Characteristics of the population were described by using proportions for categorical variables and median and range for quantitative variables since their distributions were tested with the Shapiro-Wilk statistic and were mostly skewed.
Associations between the extent of CAC divided into three groups (,100, [100-400[, $400) and patient characteristics, vascular risk biomarkers, biological parameters were quantified with odds-ratio (OR) and their 95% confidence intervals (CI). Clinical and sociodemographic variables associated with CAC (at p,0.15) were included in multinomial logistic regression models to estimate adjusted OR for biological parameters (especially OPG and FGF23). The cut-off used for CAC has been chosen by respect to CAC scoring: those with CAC,100 (considered as patients with insignificant or mild CAC), those with CAC in the range [100-400[ (presence of moderate CAC) and those with CAC$400 (presence of severe CAC) [19, 20] . Biological parameters were divided into tertiles. In the case of FGF23 and OPG, patients were divided into two categories, those with a low level (,173.30 RU/ mL for FGF23; ,10.71 pmol/L for OPG, corresponding to the 1st and 2nd tertiles) and those with a high level ($173.30 RU/mL for FGF23; $10.71 pmol/L for OPG, corresponding to the 3rd tertile).
Spearman correlation coefficient (rho) was used to determine the relationships between quantitative variables.
Significance was set at p,0.05. All analyses were carried out with SAS software, version 9.2 (SAS Institute, Cary, NC, USA).
Results
Clinical characteristics for the 195 CKD patients are summarized in Table 1 
Prevalence of high OPG and FGF-23 levels according to the extent of CAC
To further compare the relative prevalence of abnormally high (greater than the lower bound of third tertile) OPG versus FGF23 levels across the spectrum of CAC, the proportions of participants with normal or high OPG and FGF23 values within each category of CAC were determined. (Figure 2A) . As expected, the predominant pattern in the range of insignificant or mild CAC (,100) was normal FGF23/normal OPG (63.3%). In the range of moderate CAC, an isolated increase in OPG (46.0%) was the most common pattern and was more likely than an isolated increase in FGF23 (28.0%). By contrast, at the level of severe CAC, the most common pattern was characterized by an isolated increase in FGF23 (47.0%). 
Relationships between OPG/FGF23 (as a composite criterium) and the extent of CAC
Discussion
In this study, clinical variables such as age, diabetes mellitus and smoking habits were associated with CAC in our population of ND-CKD patients. Among biomarkers of vascular calcifications, our results clearly confirmed that both high OPG and FGF23 levels were associated with CAC in this population. Original findings of our study are that association of both markers with CAC depends on the severity of CAC extension: OPG is associated to moderate CAC while FGF23 rather represents a biomarker of severe CAC in these patients. Previous studies have reported an association between high OPG levels and CAC in CKD (in particular one from our group) [6] , HD [7, 10, 21] and diabetic patients [22, 23] . Here, we demonstrated for the first time that high OPG is only associated to moderate rather than severe coronary calcifications. These interesting results are in total agreement with a previous study from Morony et al. [24] in a model of atherogenic diet-fed ldlr (2/2) mice. Indeed, the authors clearly showed that plasma OPG level increased with initiation of the atherogenic diet, reached a maximum value after one month of diet and did not increase further during the four following months while aortic atherosclerosis lesions were still progressing. In our Table 3 . Biological markers associated to increased coronary artery calcifications after adjustment for age, gender, diabetes mellitus and smoking (the p-value of the test for trend is given). study, the same pattern is observed. OPG values are significantly increased in patients with moderate ([100-400[) compared with mild (,100) CAC, this increased level being comparable with that of patients presenting severe (.400) CAC. This clearly suggests that OPG appears as a marker of atherosclerosis/vascular calcification onset rather than its severity or progression. Considerable controversy exists regarding the role of OPG in the development and progression of vascular calcifications. However, the only theory we can speculate on is that OPG is increased in response to vascular insult as the component of a complex compensatory mechanism, probably secondary to inflammatory processes. Indeed, proinflammatory mediators, particularly TNF-alpha, which participate to the development of vascular calcification through induction of alkaline phosphatase can also stimulate OPG synthesis in vascular smooth muscle cells and endothelial cells [25] [26] [27] in an attempt to possibly counteract osteogenic or pro-apoptotic calcification mechanisms. However, further in vitro and in vivo studies need to be conducted in order to elucidate the exact implication of such molecule in the early progression of vascular calcifications. Regarding FGF23, although its association with CAC was evidenced in HD [8, 9] , this relationship was not clear in all studies related to ND-CKD patients. In their analysis, Gutierrez et al. [11] could describe an association between FGF23 and CAC. However, this association was no longer significant after multivariable adjustment or when examined on a continuous scale. The recent study from Desjardins et al. [28] clearly demonstrated in 142 ND-CKD patients an association between high FGF23 and aortic calcifications and to a lesser extent an association with CAC in a subgroup of 93 patients. As previously observed by Gutierrez et al., FGF23 was also no longer associated to CAC in their multivariate analysis. The authors speculated that, contrary to aortic calcifications, the lack of association between CAC and FGF23 may be explained by the different type of calcifications observed (intimal for coronaries and medial in the case of aorta): FGF23 being more related to mineral metabolism disturbances, would favor medial rather than intimal atheromatous calcifications. Actually, the persisting association between CAC and FGF23 after full adjustment, observed here, in more than twice the number of patients, may probably reflect a power limitation of their study. Desjardins et al. also depicted correlations between aortic as well as coronary calcifications and FGF23. In the present study, we were not able to evidence any correlation, as our results clearly demonstrated an association between FGF23 and severe rather than moderate CAC. Interestingly, these latter findings were also described in the study from Jean et al. in HD patients [10] .
The potential evidence of high FGF23 as a biomarker of severe CAC in our study cannot lead to the conclusion of a real role of FGF23 in the pathogenesis of CAC. Indeed, it was initially postulated that FGF23, due to its phosphaturic and hypophosphatemic actions [29] , may be considered as a protective molecule against vascular calcifications. During decline in renal function, the commonly observed rise in FGF23 should probably reflect an increased production by osteocytes to help maintening normophosphatemia rather than a lack of removal by the kidney [30] . However, a previous work in this population could report a preponderance of C-terminal fragments (secondary to proteolytic cleavage of intact FGF23) suggesting that less than one-quarter of the circulating FGF23 was bioactive in these patients [31] . In addition, the original work from Goetz et al. [32] could provide evidence that proteolytic cleavage of this molecule abrogated its activity by removing FGF23's binding site for the FGF receptorKlotho complex and also by generating an endogenous inhibitor of FGF23. Therefore, taken into account all these findings, it could be postulated that the high levels of FGF-23 (both intact and Cterminal fragments) measured in our population might reflect a lack of efficiency rather than an excess activity of this phosphatonin. However, importantly we observed a significant association between high levels of FEPO 4 , the first target of FGF23, and CAC. Finally, as no association was reported between phosphatemia and CAC in our study, we may also assume that such association between FGF23 and CAC involves phosphateindependent mechanismes. Indeed, the recent report of Faul et al. [33] in an animal model strongly suggests that FGF-23 per se is able to induce an impairment in cardiac function. Besides, the lack of association observed here between serum phosphate and CAC is surprising but not unexpected as previous studies also reported similar findings in predialysis patients [2, 34] . Russo et al. suggested that a single measurement of serum phosphate could not reflect the lifetime exposure due to rapidly changes over time for compensatory mechanisms that are mostly active early in the course of CKD [35] .
Our study acknowledged some limitations. Both intact FGF23 and C-terminal fragments have been measured here. Even though several studies reported strong correlations (r = 0.97; p,0.0001) existing with the active intact FGF23 [36] , this assay does not exactly reflect the biologically active form of FGF23. However, it is to note that a strong positive correlation (rho = 0.52731; p,0.0001) was observed here between C-terminal fragments and FEPO 4 , the intact FGF23 first target. Circulating klotho levels are missing due to the lack of availability of assays in plasma or urine. The relatively small sample size of this study may have prevented some of the detected associations from being statistically significant. Finally, the cross-sectional nature of this study can not clearly evidence the kinetic of OPG and FGF23 over the progression of coronary calcifications, a prospective study being strongly required.
In conclusion, even though both OPG and FGF23 constitute strong predictors of mortality in HD patients, their relationships to vascular calcifications are different, especially in ND-CKD population. Our results clearly showed that both high OPG and FGF23 levels were associated with CAC in this population of ND-CKD patients, OPG being nevertheless a stronger associated factor of moderate CAC while FGF23 rather represents a biomarker of severe CAC.
